NVN Liquidation Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 0/6
NVN Liquidation has been growing earnings at an average annual rate of 6.1%, while the Pharmaceuticals industry saw earnings declining at 0.9% annually. Revenues have been growing at an average rate of 512.7% per year.
Anahtar bilgiler
6.1%
Kazanç büyüme oranı
29.0%
EPS büyüme oranı
Pharmaceuticals Sektör Büyümesi | 14.1% |
Gelir büyüme oranı | 512.7% |
Özkaynak getirisi | n/a |
Net Marj | -128.6% |
Son Kazanç Güncellemesi | 31 Mar 2023 |
Yakın geçmiş performans güncellemeleri
Recent updates
Gelir ve Gider Dağılımı
NVN Liquidation nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
---|---|---|---|---|
31 Mar 23 | 25 | -32 | 38 | 0 |
31 Dec 22 | 24 | -31 | 34 | 0 |
30 Sep 22 | 14 | -37 | 31 | 0 |
30 Jun 22 | 9 | -37 | 26 | 0 |
31 Mar 22 | 4 | -34 | 16 | 0 |
31 Dec 21 | 3 | -30 | 12 | 0 |
30 Sep 21 | 3 | -28 | 11 | 0 |
30 Jun 21 | 4 | -30 | 11 | 0 |
31 Mar 21 | 5 | -32 | 11 | 0 |
31 Dec 20 | 5 | -29 | 11 | 0 |
30 Sep 20 | 5 | -29 | 11 | 3 |
30 Jun 20 | 5 | -30 | 10 | 7 |
31 Mar 20 | 5 | -30 | 10 | 11 |
31 Dec 19 | 5 | -30 | 10 | 15 |
30 Sep 19 | 8 | -17 | 11 | 15 |
30 Jun 19 | 7 | -15 | 12 | 15 |
31 Mar 19 | 6 | -14 | 12 | 15 |
31 Dec 18 | 6 | -13 | 12 | 15 |
30 Sep 18 | 3 | -28 | 11 | 15 |
30 Jun 18 | 3 | -28 | 11 | 15 |
31 Mar 18 | 3 | -30 | 12 | 11 |
31 Dec 17 | 3 | -37 | 13 | 14 |
30 Sep 17 | 2 | -42 | 14 | 13 |
30 Jun 17 | 1 | -52 | 14 | 11 |
31 Mar 17 | 0 | -60 | 14 | 13 |
31 Dec 16 | 0 | -60 | 13 | 9 |
30 Sep 16 | 0 | -57 | 13 | 8 |
30 Jun 16 | 0 | -45 | 13 | 7 |
31 Mar 16 | 0 | -32 | 11 | 6 |
31 Dec 15 | 0 | -26 | 9 | 5 |
30 Sep 15 | -3 | -21 | 7 | 2 |
31 Dec 14 | 0 | -13 | 5 | 2 |
31 Dec 13 | 3 | -6 | 4 | 3 |
Kaliteli Kazançlar: 0A4P is currently unprofitable.
Büyüyen Kar Marjı: 0A4P is currently unprofitable.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: Insufficient data to determine if 0A4P's year-on-year earnings growth rate was positive over the past 5 years.
Büyüme Hızlandırma: Unable to compare 0A4P's earnings growth over the past year to its 5-year average as it is currently unprofitable
Kazançlar vs. Sektör: 0A4P is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.6%).
Özkaynak Getirisi
Yüksek ROE: 0A4P's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.